Can you take Ozempic and semaglutide together?

Step 1: Understand what Ozempic actually is

Ozempic is a brand name manufactured by Novo Nordisk. The active ingredient is semaglutide, a GLP-1 receptor agonist delivered by once-weekly subcutaneous injection. Another Novo Nordisk brand, Wegovy, contains the same molecule at a higher maintenance dose (up to 2.4 mg, or the newer 7.2 mg) and carries a UK licence specifically for weight management.

So when someone asks whether you can take Ozempic and semaglutide together, they are effectively asking whether you can take semaglutide and semaglutide together. The NHS is clear on this: Ozempic is licensed for type 2 diabetes in the UK, not for weight loss. You can read more about semaglutide's different licensed uses on our semaglutide overview page. Combining any two products that share an active ingredient is not a recognised clinical practice and would expose you to dose levels far outside anything studied for safety.

It is worth noting the same logic applies if anyone asks about taking Ozempic and Wegovy together. Both are semaglutide. The answer does not change because the brand names differ.

Step 2: Know what the safety risks actually are

Doubling up on semaglutide would not produce twice the weight loss. It would produce an uncontrolled, excessive dose with no clinical backstop. GLP-1 medicines at standard doses already carry a well-characterised gastrointestinal side-effect profile: nausea, vomiting, diarrhoea, constipation and reflux are common at the start of treatment or after a dose increase, typically settling within days to a couple of weeks as the body adjusts.

Push the effective dose far beyond what is prescribed, and those effects become more severe and harder to manage. More seriously, the MHRA issued a Drug Safety Update in January 2026 highlighting acute pancreatitis as an infrequent but potentially serious risk with GLP-1 medicines. Severe, persistent stomach pain that radiates to the back (with or without vomiting) requires urgent medical attention. The MHRA's Yellow Card scheme is where patients and clinicians can report suspected adverse effects from any medicine.

There is also the question of supply. Semaglutide has at various points been subject to availability pressures in the UK. Obtaining a second product to run alongside a prescribed one would almost certainly mean sourcing it from outside a legitimate clinical relationship, which brings its own serious risks around counterfeit and unregulated supply.

Step 3: Know which medicines are actually licensed for weight loss in the UK

Two injectable GLP-1 medicines hold UK licences specifically for weight management in adults: Wegovy (semaglutide) and Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist made by Eli Lilly. A third option (oral semaglutide under the Wegovy tablet brand) received MHRA approval in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK.

Ozempic is not on that list. It is licensed for type 2 diabetes. Using it off-label for weight loss is a matter between a patient and their diabetes team; it is not something a weight-management service prescribes. If you are curious about how Wegovy compares to other options, or what private treatment costs in the UK, our Wegovy price comparison page gives an honest breakdown of what to expect. For questions that go beyond semaglutide entirely (such as whether combining two different GLP-1 classes is ever done) our page on taking semaglutide and liraglutide together covers the reasoning there.

Other combination questions come up too: some patients ask about peptides, supplements or other medicines alongside semaglutide. Our pages on MOTS-c and semaglutide and on antibiotics and semaglutide address those separately. The short version is always the same: check with your prescriber before adding anything.

What to do if you are already on Ozempic and want weight-loss treatment

If you are currently prescribed Ozempic for diabetes and are also looking to manage your weight, talk to your diabetes team first. Switching to or adding a separate weight-management medicine is a clinical decision that requires full visibility of your medical history, current medicines and diabetes control. It is not a self-directed step.

For people who are not on a diabetes medicine and are exploring weight-loss treatment for the first time, the starting point is understanding which licensed options suit your circumstances. Our Ozempic and semaglutide explainer sets out the distinction between the brands clearly. If you are ready to explore whether a licensed weight-management medicine is clinically appropriate for you, a free consultation with a GPhC-registered prescriber at nume's weight-loss treatment page is where that conversation begins. A real clinician reviews your answers the same day, no algorithms, no automated sign-offs. The NHS semaglutide page is also a reliable starting point for understanding what semaglutide is and how it works before any consultation.